UCLA Health

New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods

Retrieved on: 
수요일, 5월 8, 2024
UCLA, FDA, ECS, AI, American Urological Association, Health, Unfold, MD, PSA, Doctor of Philosophy, Prostate cancer, GG5, Patient, GG1, Physician, AUA, MRI, Biopsy, UCLA Health, Neoplasm, GG, Quality of life, Cryotherapy, Medical imaging

CULVER CITY, Calif., May 8, 2024 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments. The study titled "Software to Determine Extent of Tumor Margins in Focal Therapy," was presented at the 2024 American Urological Association's (AUA) annual meeting by Wayne Brisbane, MD, assistant professor at UCLA Health. It demonstrated that Unfold AI, Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.

Key Points: 
  • It demonstrated that Unfold AI , Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.
  • In the study, FDA-cleared Unfold AI technology was retrospectively applied to 118 previously untreated men undergoing hemi-gland cryotherapy for prostate cancer ablation.
  • MRI-guided biopsies, both targeted and systematic, were performed before cryotherapy and six months after cryotherapy to assess treatment outcomes.
  • "This more comprehensive approach enhances our ability to predict treatment outcomes and tailor interventions effectively to individual patient needs."

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
수요일, 5월 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, Multimedia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/texas-cardiac-arrhythmia-instit...
    SOURCE Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
수요일, 5월 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • Physicians received a maximum of 14.5 American Medical Association (AMA) Physician's Recognition Award (PRA) Category 1 Credit™ hours at the conference.

Studies Find Disparities in Urologic Cancer Diagnosis and Care for Black Americans

Retrieved on: 
금요일, 5월 3, 2024
American Urological Association, Black, Abstract (summary), Mortality, Abstract, UCLA Health, MD, Research, SAN, Face

Researchers will present their study findings covering disparities and urologic cancer in San Antonio, TX, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering disparities and urologic cancer in San Antonio, TX, from May 3 to 6.
  • Adam Weiner, MD, urologist at UCLA Health, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “These abstracts stood out in terms of relevance and potential impact for the urology field,” said Dr. Weiner.
  • “We have examples of ecological studies, retrospective cohort studies, and qualitative studies that all aim to highlight and address disparities in urological cancer outcomes.”
    The following abstracts are covered in the moderated panel:

The 22nd Annual OneLegacy Run/Walk Closes Donate Life Month Celebrations Gathering Thousands of Donor Families, Grateful Recipients and Donation Advocates at Azusa Pacific University to Honor the Gift of Life

Retrieved on: 
목요일, 5월 2, 2024
Other Health, Music, Other Communications, Publishing, Optical, Public Relations, Investor Relations, Marketing, Entertainment, Advertising, Communications, Social Media, Hospitals, Celebrity, Fund Raising, Foundation, University, Education, Philanthropy, Medical Supplies, Health, Other Philanthropy, General Health, Run, ABC, Azusa Pacific University, DMV, Hospital, Foreign policy, Thermo Fisher Scientific, City, CBS News, ABC 7, Mexican cuisine, Life, Yoga, CBS, Friends, Oxygen, Eye, USC, Communication, Multimedia, Memory, UCLA Health, Meditation, Medical device

More than 200 teams and over 20 exhibitors participated in this special event, which marked the culmination of Donate Life month.

Key Points: 
  • More than 200 teams and over 20 exhibitors participated in this special event, which marked the culmination of Donate Life month.
  • View the full release here: https://www.businesswire.com/news/home/20240502456947/en/
    Nearly 4,000 deceased donor families, transplant recipients and donation advocates gathered last Saturday, April 27 at Azusa Pacific University to celebrate the 22nd Annual OneLegacy Donate Life Run/Walk.
  • Assemblymember Blanca Rubio, Azusa Mayor Robert Gonzales and Donate Life California’s CEO, Jim Martin, shared special remarks during the opening ceremony.
  • All proceeds from the 22nd Annual OneLegacy Donate Life Run/Walk will benefit the OneLegacy Foundation’s public education programs, with the goal of inspiring local communities to donate life.

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Retrieved on: 
수요일, 3월 27, 2024
Capacity utilization, Diagnosis, Research, RSA, Bone marrow, TCT, Rituximab, Cell, General counsel, Health, Patient, EAP, Highbridge Capital Management, Society, Ronald Reagan, ATM, Depreciation, ID, Transplant, Therapy, Medicare, NK, CMS, Marketing, UCLA Health, Dentistry

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Gamida Cell will become a private company, wholly owned by Highbridge, and the company’s outstanding ordinary shares are expected to be canceled.
  • The company has confirmed coverage with payers who cover more than 90% of commercial lives, exceeding the 2023 goal of 70%.
  • The full year Net Revenue included $1.1 million of net review for the fourth quarter of 2023.

Paragonix Technologies Announces Nationwide Commercial Availability of FDA-Cleared BAROguard™ Donor Lung Preservation System

Retrieved on: 
목요일, 4월 4, 2024
FDA, Health Technology, Health, Medical Devices, Lung, Massachusetts General Hospital, International Society, Transplant, Patient, Duke University Hospital, Research, Standard of care, Lung transplantation, MD, Surgeon, MSC, UCSF Medical Center, Atmosphere, Hospital, UCLA, Heart, UCLA Health, Medical device

Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .

Key Points: 
  • Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .
  • First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection.
  • Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023.
  • “The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.

UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence

Retrieved on: 
화요일, 4월 2, 2024
HER2, Brain, Algorithm, Entrepreneurship, Immunotherapy, Disease, Risk, UCLA Health, Patient, Triple-negative breast cancer, Neoplasm, Research, MD, Medicine, Hospital, Breast cancer, Risk assessment, Pathology, Prognosis, Medical laboratory, Recurrence, TNBC, UCLA, Artificial intelligence, Health, Medical imaging

NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's™ ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases, yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics. 

Key Points: 
  • Our collaboration with PreciseDx has the potential to greatly improve our approach to predicting and managing recurrence in TNBC patients, ultimately leading to enhanced outcomes."
  • Integrating advanced AI algorithms and comprehensive clinical data, the collaborative study aims to confirm PreciseBreast as a highly effective and reliable digital breast cancer assay.
  • This new assay will potentially enhance the early detection of TNBC recurrence and support personalized treatment strategies tailored to individual patient needs.
  • The collaborative study between UCLA and PreciseDx represents a significant step forward in digital pathology and oncology breast cancer research.

NEW BOOK ENERGIZES MID-CAREER WOMEN BY PROMOTING INTENTIONAL SELF-ADVOCACY AND REJECTING SOCIETAL NORMS THAT HOLD WOMEN BACK

Retrieved on: 
화요일, 3월 19, 2024
Salvatore Ferragamo S.p.A., The Wall Street Journal, Next, USA Today, Zeal, The New York Times, Woman, The Ritz-Carlton Hotel Company, The Cheesecake Factory, Talent, Sale, University, Heel, Barnes & Noble, Publishing, Delta Air Lines, Multimedia, UCLA Health, Management

The book is on sale now via Amazon , Barnes & Noble , Amplify Publishing , and other major retailers.

Key Points: 
  • The book is on sale now via Amazon , Barnes & Noble , Amplify Publishing , and other major retailers.
  • Cynthia Bentzen-Mercer, cofounder of The Zeal of the Heel and founder of Bentzen Performance Partners, is a business executive, human capital strategist, author, and executive coach.
  • Kimberly is also the Wall Street Journal and USA Today bestselling author of Business Success Secrets.
  • Now, Near, Next is on sale now from Amazon , Barnes & Noble , Amplify Publishing , and other major retailers.

CrownLine to Launch 'Jupiter Column': Community for People to Leverage Proprietary Method Illuminating Human Relationship Chemistry

Retrieved on: 
금요일, 2월 16, 2024
Online, Engineering, Anxiety, Algorithm, Mental health, Student, Connected, Chemistry, University, Suicide, Thought, Family tree, Loneliness, Calendar, Stroke, Club, Sport, Season, Risk, Health, Depression, Autumn, Population health, Family, Dementia, Public, Medicine, Bullying, UCLA Health, Number, Music, Charm bracelet, Online shopping

LOS ANGELES, Feb. 16, 2024 /PRNewswire-PRWeb/ -- CrownLine (www.crownline.io), a company focused on illuminating human relationship chemistry, announced it will launch in the month of March 2024 "Jupiter Column", the community of CrownLine. Available to members via subscription, people can learn, and personally benefit from, the CROWNLINE Method to enhance and understand their human relationships -- be they identifying and connecting with individuals for friendship, family, business, potential significant others, and even a soulmate.

Key Points: 
  • LOS ANGELES, Feb. 16, 2024 /PRNewswire-PRWeb/ -- CrownLine ( www.crownline.io ), a company focused on illuminating human relationship chemistry, announced it will launch in the month of March 2024 "Jupiter Column", the community of CrownLine.
  • CrownLine Founder and CEO Todd Anthony Person has spent over two decades studying and building the foundation that would become the CrownLine Method.
  • The deck of playing cards was originally used as a calendar: there are 52 cards representing the 52 weeks in the year.
  • "Having confidence in one's relationships is key to mental health, and CrownLine intends to develop mentorship programs as part of its community relations efforts," commented Person.